SCHEMBL3381954

SCHEMBL3381954

O=C(O)Oc1cc2cc(Br)ccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.48
CYP19A1 P11511 1/20 0.46
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
BCAT1 P54687 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
PYGL P06737 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381701 0.87 HRH4 (0.43) HRH4AHRNCEH1
SCHEMBL29056767 0.85 FLT3 (0.47) FLT3CYP19A1HRH4HRH3BCAT1
SCHEMBL5155719 0.81 SMAD3 (0.57) FLT3HRH4
SCHEMBL18886841 0.80 GABRA1 (0.46) FLT3HRH4HRH3NPC1
SCHEMBL3418659 0.80 PIN1 (0.58) FLT3HRH4MEN1KMT2APOLB
SCHEMBL3414863 0.80 KDM4E (0.58) FLT3HRH4HDAC3HDAC4HDAC1
SCHEMBL3412727 0.80 F7 (0.58) FLT3CYP19A1HRH4HRH3MEN1
SCHEMBL3419450 0.78 PDGFRB (0.60) FLT3HDAC6MEN1KMT2APOLB
SCHEMBL1833251 0.77 KDM4E (0.55) FLT3IDO1NPC1CYP2A6
SCHEMBL6264258 0.76 KDM4E (0.51) HRH3MEN1KMT2ANPC1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968272-B1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2021-06-16 EP claimed
EP-1599203-B1 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS SANOFI AVENTIS DEUTSCHLAND (DE) 2013-10-23 EP disclosed
EP-2149554-A1 Indolyamides as modulators for an EP2 receptor Bayer Schering Pharma Aktiengesellschaft (DE) 2010-02-03 EP disclosed
EP-1519726-B1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-02-21 EP disclosed
EP-1749529-A1 Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases SCHWARZ PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1519726-A1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SCHWARZ PHARMA AG (DE) 2005-04-06 EP disclosed
WO-2004004729-A1 UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES SCHWARZ PHARMA AG (DE) 2004-01-15 WO disclosed